Direct Flow Medical, Inc. Completes First Human Use of 18F Percutaneous Aortic Valve System

SANTA ROSA, Calif.--(BUSINESS WIRE)--Direct Flow Medical, Inc. a privately held, emerging medical device Company developing a next generation, minimally invasive implant to treat patients with heart valve disease announced today the first human use of their new 18 French Percutaneous Aortic Valve (PAV) System. The 18F system was used to successfully treat two high risk surgical candidates at Dante Hospital in San Paolo, Brazil. The procedures were performed by Dr. Cesar Esteves and assisted by Dr. Reginald Low and Professor Eberhard Grube. In the first patient treated with the 18F PAV system the physicians were able to safely complete the first ever successful retrieval of the device through an 18F sheath before easily positioning and deploying a second device.